Meridiem Capital Partners LP 10x Genomics, Inc. Transaction History
Meridiem Capital Partners LP
- $1.14 Trillion
- Q4 2024
A detailed history of Meridiem Capital Partners LP transactions in 10x Genomics, Inc. stock. As of the latest transaction made, Meridiem Capital Partners LP holds 342,870 shares of TXG stock, worth $4.15 Million. This represents 0.43% of its overall portfolio holdings.
Number of Shares
342,870Holding current value
$4.15 Million% of portfolio
0.43%Shares
1 transactions
Others Institutions Holding TXG
# of Institutions
302Shares Held
96.5MCall Options Held
76.4KPut Options Held
132K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$145 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$132 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.39MShares$77.4 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.5.71MShares$69.1 Million0.92% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.5.71MShares$69.1 Million0.06% of portfolio
About 10x Genomics, Inc.
- Ticker TXG
- Exchange NASDAQ
- Sector Healthcare
- Industry Health Information Services
- Shares Outstandng 95,046,400
- Market Cap $1.15B
- Description
- 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumabl...